Barclays Gets Bullish On US Biotechnology Sector (BBH)
More News related to ACAD
- Acadia Pharmaceuticals (ACAD) Tops Q3 EPS by 1c
- ACADIA Pharmaceuticals Reports Third Quarter 2009 Financial Results
- ACADIA Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 9, 2009
- ACADIA Pharmaceuticals to Present at the BIOCOM Investor Conference on October 26, 2009
- ACADIA Pharma (ACAD) to Cut Workforce by 50%
More News related to AMGN
- Amgen Highlights Data to be Presented at ASH
- Beacon Equity Issues Technical Trading Overview for NexMed Inc.
- Amgen Recognized for Best Pipeline and Best New Drug at Scrip Awards
- Amgen to Present at Lazard Capital Healthcare Conference
- Amgen to Present at 18th Annual Credit Suisse Healthcare Conference
More News related to ARNA
- Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
- StockPreacher.com Issues Trading Outlook for Arena Pharmaceuticals Inc.
- Arena Pharmaceuticals, Inc. (ARNA) Posts Q3 Loss of $0.38, Misses by 4c
- Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments
- Trading Radar for 11/09: Dish Network (DISH), Rockwell (ROK), Priceline.com (PCLN), MBIA (MBI), Ticketmaster (TKTM) Report
More News related to Upgrades
- ConocoPhillips (COP) Approves $11.2 Billion CapEx Plan For 2010
- GM's Chairman, Ed Whitacre, has said that the search for a CEO could take as long as a year
- General Dynamics (GD) Team Awarded U.S. Army Contract Worth Up To $200 Million
- STEC (STEC) Falls On Reports Micron (MU) To Enter Its Market
- Mead Johnson Loses $13.5 Million Lawsuit to PBM Products
Biotech HOLDRs (NYSE: BBH) is seeing some upside action today after the biotech industry received its second major upgrade in the past few weeks. The ETF is up 1% today.
Today, Barclays upgraded the US Biotechnology sector from Neutral to Positive, citing valuation and saying they see significant opportunity for the group into 2nd-half of 2009.
With the sector call, the firm also upgraded Biogen Idec (Nasdaq: BIIB) from Underweight to Equal Weight and raised its price target to $52.
The firm's top rated biotech picks in the sector include Amgen (Nasdaq: AMGN), Celgene (Nasdaq: CELG), Genzyme (Nasdaq: GENZ), Cephalon (Nasdaq: CEPH), Acadia (Nasdaq: ACAD), Arena (Nasdaq: ARNA), Rigel (Nasdaq: RIGL), Array (Nasdaq: ARRY), Onyx (Nasdaq: ONXX), Isis (Nasdaq: ISIS), Regeneron (Nasdaq: REGN)
Earlier in the month, Goldman Sachs upgraded U.S. Large Cap Biotechs to Neutral.
Related Categories
UpgradesStocks Mentioned
-0.04
+0.35Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
